Nektar Therapeutics continues run in 2017 with Positive Data for NKTR-181 in Chronic Lower Back Pain

Nektar Therapeutics (NASDAQ: NKTR) announced on March 20th that NKTR-181 met its primary and several secondary endpoints in chronic lower back pain.

Patients on NKTR-181 experienced a 65% reduction in pain score prior to randomization. Following randomization, the difference in mean change in pain scores was 1.25 vs 0.56, respectively in the placebo and NKTR-181 arms. NKTR-181 demonstrated sustained pain relief over the 12 weeks of the study and patients on NKTR-181 saw general improvements in sleep patterns.

According to management, NKTR-181 may not need additional study to gain marketing approval. They plan to talk to potential interested companies within the next 3 months who have a strong standing in the pain field with the goal of establishing a strategic collaboration.

Nektar is one of AMP Biotech Research's quarterly picks for Q1 2017. AMP is a biotech research firm that publishes a quarterly list of companies with attractive valuations and near-term catalysts. To see all of AMP's picks for Q1 2017, go to

Find the original press release here:

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon